Antibody-Targeted Interleukin 2 Stimulates T-Cell Killing of Autologous Tumor Cells

• Published in: Proceedings of the National Academy of Sciences - PNAS Vol. 89; no. 4; pp. 1428 - 1432
• Main Authors: Gilles, Stephen D., Reilly, Edward B., Lo, Kin-Ming, Reisfeld, Ralph A.
• Format: Journal Article
• Language: English
• Published: Washington, DC National Academy of Sciences of the United States of America 15.02.1992; National Acad Sciences; National Academy of Sciences
• Subjects: Antibodies; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - chemistry; Antibody dependent cell cytotoxicity; Antigens; Biological and medical sciences; Cancer; Cellular immunity; Cytotoxic reactions (adcc reaction, cell-mediated lympholysis, complement-dependent cytotoxicity and others); Cytotoxicity, Immunologic; Drugs; Fundamental and applied biological sciences. Psychology; Fundamental immunology; Gangliosides - immunology; Humans; Immunity (Disease); Immunobiology; Immunological reactions in vitro; In Vitro Techniques; Interleukin-2 - administration & dosage; Interleukin-2 - chemistry; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating - immunology; Medical research; Melanoma; Melanoma - immunology; Natural killer cells; Proteins; Recombinant Fusion Proteins - pharmacology; T lymphocytes; T-Lymphocytes - immunology; Tumor cell line; Tumors; Human; Antibody; Cytokine; Melanoma; Cytotoxicity; Autologous system; In vitro; Ganglioside; Interleukin 2; Immunotherapy; Antibody-dependent cell cytotoxicity; T-Lymphocyte; Tumor; Target cell; Chimera

A genetically engineered fusion protein consisting of a chimeric anti-ganglioside GD2 antibody (ch14.18) and interleukin 2 (IL2) was tested for its ability to enhance the killing of autologous GD2-expressing melanoma target cells by a tumor-infiltrating lymphocyte line (660 TIL). The fusion of IL2 t...